Fig. 8
From: Mesenchymal stem cell-mediated delivery of therapeutic adenoviral vectors to prostate cancer
CRAd-loaded MSCs-E1s or Adbic-loaded MSCs-E1s have antitumor effects on subcutaneous human Ki-ras prostate tumors in nude mice. a, b Male nude mice bearing subcutaneous Ki-ras cell tumors (vol ~ 50 mm3) were randomized into five groups of seven mice and intratumoral treatments were initiated (day 1). Experimental groups for CRAd received either 5 × 105 MSCs-E1s loaded with 3 × 107 pfu/cell of CRAd vector or free CRAd vector (3 × 107 pfu/mouse). Experimental groups for Adbic received either 5 × 105 MSCs-E1s loaded with 3 × 107 pfu/cell of Adbic or free Adbic (3 × 107 pfu/mouse). Treatments [see arrows (▲)] were repeated on days 5 and 9 of treatment. Control groups did not receive any treatment. At the end of the treatment, mice models were euthanized and tumor volumes measured by the formula (tumor volume = ½ L × w2). Results showed that both types of treatments have significantly (P < 0.05) reduced the tumor volume as compared to the control group